WO2006102395A3 - Systemes et methodes d'administration pour le diagnostic et le traitement de maladies cardio-vasculaires - Google Patents

Systemes et methodes d'administration pour le diagnostic et le traitement de maladies cardio-vasculaires Download PDF

Info

Publication number
WO2006102395A3
WO2006102395A3 PCT/US2006/010371 US2006010371W WO2006102395A3 WO 2006102395 A3 WO2006102395 A3 WO 2006102395A3 US 2006010371 W US2006010371 W US 2006010371W WO 2006102395 A3 WO2006102395 A3 WO 2006102395A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
diagnosing
methods
delivery systems
cardiovascular diseases
Prior art date
Application number
PCT/US2006/010371
Other languages
English (en)
Other versions
WO2006102395A2 (fr
Inventor
Stephen E Epstein
Mary Susan Burnett
Martin A Mullins
Original Assignee
Medstar Health Inc
Univ Georgetown
Stephen E Epstein
Mary Susan Burnett
Martin A Mullins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medstar Health Inc, Univ Georgetown, Stephen E Epstein, Mary Susan Burnett, Martin A Mullins filed Critical Medstar Health Inc
Priority to CA002602946A priority Critical patent/CA2602946A1/fr
Priority to JP2008503125A priority patent/JP2008534508A/ja
Priority to EP06739249A priority patent/EP1866416A2/fr
Priority to AU2006227133A priority patent/AU2006227133A1/en
Publication of WO2006102395A2 publication Critical patent/WO2006102395A2/fr
Publication of WO2006102395A3 publication Critical patent/WO2006102395A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne le traitement et la prévention de l'athérosclérose et de maladies cardio-vasculaires associées à l'athérosclérose. La présente invention porte également sur des méthodes pour diagnostiquer l'athérosclérose et des maladies cardio-vasculaires associées à l'athérosclérose. Dans certains modes de réalisation, des systèmes et des procédés biologiques permettent d'administrer un agent thérapeutique ou un agent d'imagerie sur des lésions d'athérosclérose telles que des plaques vulnérables.
PCT/US2006/010371 2005-03-22 2006-03-22 Systemes et methodes d'administration pour le diagnostic et le traitement de maladies cardio-vasculaires WO2006102395A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002602946A CA2602946A1 (fr) 2005-03-22 2006-03-22 Systemes et methodes d'administration pour le diagnostic et le traitement de maladies cardio-vasculaires
JP2008503125A JP2008534508A (ja) 2005-03-22 2006-03-22 心血管疾患を診断および処置するための送達システムおよび方法
EP06739249A EP1866416A2 (fr) 2005-03-22 2006-03-22 Systemes et methodes d'administration pour le diagnostic et le traitement de maladies cardio-vasculaires
AU2006227133A AU2006227133A1 (en) 2005-03-22 2006-03-22 Delivery systems and methods for diagnosing and treating cardiovascular diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66430005P 2005-03-22 2005-03-22
US60/664,300 2005-03-22

Publications (2)

Publication Number Publication Date
WO2006102395A2 WO2006102395A2 (fr) 2006-09-28
WO2006102395A3 true WO2006102395A3 (fr) 2007-05-10

Family

ID=36930417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/010371 WO2006102395A2 (fr) 2005-03-22 2006-03-22 Systemes et methodes d'administration pour le diagnostic et le traitement de maladies cardio-vasculaires

Country Status (6)

Country Link
EP (1) EP1866416A2 (fr)
JP (1) JP2008534508A (fr)
CN (1) CN101189339A (fr)
AU (1) AU2006227133A1 (fr)
CA (1) CA2602946A1 (fr)
WO (1) WO2006102395A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066978B2 (en) 2010-05-26 2015-06-30 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
ES2442594T3 (es) * 2007-03-01 2014-02-12 Csl Limited Tratamiento de la disfunción endotelial en pacientes diabéticos
US7956035B2 (en) 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
WO2008124639A2 (fr) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Fractions de ciblage de poly (acide aminé)
EP2176423A1 (fr) * 2007-07-11 2010-04-21 Koninklijke Philips Electronics N.V. Analyse de l'expression in vivo à l'aide d'une transfection ultrasonore de constructions rapporteur
EP2019318A1 (fr) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Marqueurs de protéines pour événements cardio-vasculaires
GB0811856D0 (en) 2008-06-27 2008-07-30 Ucl Business Plc Magnetic microbubbles, methods of preparing them and their uses
CN102497803B (zh) * 2009-05-05 2015-03-25 卢米托股份有限公司 用于散射介质中改进的扩散发光成像或者断层照相的系统、方法和发光标记物
EA022699B1 (ru) 2009-05-27 2016-02-29 Селекта Байосайенсиз, Инк. НАЦЕЛЕННЫЕ СИНТЕТИЧЕСКИЕ НАНОНОСИТЕЛИ С pH-ЧУВСТВИТЕЛЬНЫМ ВЫСВОБОЖДЕНИЕМ ИММУНОМОДУЛИРУЮЩИХ СРЕДСТВ
JP5463549B2 (ja) * 2009-09-08 2014-04-09 学校法人福岡大学 超音波治療用リポソーム及び超音波治療促進用リポソーム
WO2011133685A2 (fr) * 2010-04-21 2011-10-27 President And Fellows Of Harvard College Nanoparticule ciblant l'ischémie à des fins d'imagerie et de traitement
WO2011135397A1 (fr) * 2010-04-29 2011-11-03 University Of Calcutta Antiagrégant plaquettaire et procédés d'utilisation de celui-ci
CN103124904B (zh) * 2010-09-27 2015-06-03 詹森生物科技公司 食蟹猴ccl17
AU2012290306B2 (en) 2011-07-29 2017-08-17 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
CN102657875B (zh) * 2012-04-11 2013-09-04 中国人民解放军第三军医大学第二附属医院 基于ant1基因的靶向型免疫脂质体及其制备方法和应用
CN103006538A (zh) * 2012-11-09 2013-04-03 叶琳 一种用于关节炎治疗的超声微泡及其用途
US9693958B2 (en) * 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
CA2913118A1 (fr) * 2013-05-22 2014-11-27 Metabolic Engineering Laboratories Co., Ltd. Anticorps a double cible anti-tnf-?/cxcl10 et son utilisation
US9637542B2 (en) * 2013-08-21 2017-05-02 Boehringer Ingelheim International Gmbh CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease
CN105950660B (zh) * 2016-06-27 2019-11-01 姚陈 一种特异性抑制平滑肌细胞增殖和迁移的腺病毒载体及其应用
CN106474487A (zh) * 2016-11-14 2017-03-08 中国人民解放军总医院 一种靶向荧光载药纳米分子探针及其制备方法和应用
WO2018107707A1 (fr) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 Procédé pour atténuer une maladie cardiaque
CA3047181A1 (fr) 2016-12-15 2018-06-21 Talengen International Limited Methode et medicament pour la prevention et le traitement de l'obesite
CN110366425A (zh) * 2016-12-15 2019-10-22 泰伦基国际有限公司 一种预防动脉粥样硬化及其并发症的方法
WO2019215300A1 (fr) 2018-05-09 2019-11-14 Medirista Biotechnologies Ab Anticorps destinés à être utilisés en polythérapie
CN109061139A (zh) * 2018-06-19 2018-12-21 温州医科大学附属第医院 血清炎性生物标志物在防治急性缺血性脑梗死中的应用
KR20220044244A (ko) * 2019-06-05 2022-04-07 마이크로바스큘러 테라퓨틱스 엘엘씨 혈전증 및 혈관 플라크의 검출 및 치료하기 위한 조성물 및 방법
CN110201194A (zh) * 2019-07-23 2019-09-06 山东百多安医疗器械有限公司 一种治疗动脉粥样硬化斑块的载药显影微泡及其制备方法

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020701A2 (fr) * 1991-05-16 1992-11-26 Miller D Douglas Molecules ciblees sur un recepteur de l'interleukine pour le traitement de l'atherosclerose acceleree
WO1994025073A1 (fr) * 1993-04-30 1994-11-10 Rhone-Poulenc Rorer S.A. Virus recombinants et leur utilisation en therapie genique
WO1996027020A1 (fr) * 1995-03-02 1996-09-06 Rhone-Poulenc Rorer S.A. Therapie genique de l'atherosclerose par production de hdl par les lignes monocytaires
US5632991A (en) * 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
US5955584A (en) * 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
WO2000004926A2 (fr) * 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Traitement de degats tissulaires secondaires, etats inflammatoires et autres troubles, et compositions a cet effet
WO2001010450A1 (fr) * 1999-08-10 2001-02-15 Imarx Therapeutics, Inc. Agents thrombolytiques cibles
WO2001032070A2 (fr) * 1999-10-26 2001-05-10 The Regents Of The University Of California Reactifs et procedes de diagnostic, d'imagerie et de traitement d'une maladie atherosclereuse
WO2002009649A2 (fr) * 2000-08-01 2002-02-07 The University Of Kansas Conjugues peptides-medicaments integres dans des cellules
US20020168370A1 (en) * 1998-07-22 2002-11-14 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
WO2003092737A1 (fr) * 2002-04-30 2003-11-13 Molmed Spa Fusions de cytokines et de proteines de ciblage tumoral
US20050019266A1 (en) * 1997-05-06 2005-01-27 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
WO2005058153A2 (fr) * 2003-12-19 2005-06-30 Amersham Health As Agents de contraste d'imagerie optique

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955584A (en) * 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
US5632991A (en) * 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
WO1992020701A2 (fr) * 1991-05-16 1992-11-26 Miller D Douglas Molecules ciblees sur un recepteur de l'interleukine pour le traitement de l'atherosclerose acceleree
WO1994025073A1 (fr) * 1993-04-30 1994-11-10 Rhone-Poulenc Rorer S.A. Virus recombinants et leur utilisation en therapie genique
WO1996027020A1 (fr) * 1995-03-02 1996-09-06 Rhone-Poulenc Rorer S.A. Therapie genique de l'atherosclerose par production de hdl par les lignes monocytaires
US20050019266A1 (en) * 1997-05-06 2005-01-27 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
US20020168370A1 (en) * 1998-07-22 2002-11-14 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
WO2000004926A2 (fr) * 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Traitement de degats tissulaires secondaires, etats inflammatoires et autres troubles, et compositions a cet effet
WO2001010450A1 (fr) * 1999-08-10 2001-02-15 Imarx Therapeutics, Inc. Agents thrombolytiques cibles
WO2001032070A2 (fr) * 1999-10-26 2001-05-10 The Regents Of The University Of California Reactifs et procedes de diagnostic, d'imagerie et de traitement d'une maladie atherosclereuse
WO2002009649A2 (fr) * 2000-08-01 2002-02-07 The University Of Kansas Conjugues peptides-medicaments integres dans des cellules
WO2003092737A1 (fr) * 2002-04-30 2003-11-13 Molmed Spa Fusions de cytokines et de proteines de ciblage tumoral
WO2005058153A2 (fr) * 2003-12-19 2005-06-30 Amersham Health As Agents de contraste d'imagerie optique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BELIZAIRE A-K ET AL: "Identification of a murine ICAM-1-specific peptide by subtractive phage library selection on cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 309, no. 3, 26 September 2003 (2003-09-26), pages 625 - 630, XP004453645, ISSN: 0006-291X *
DEMOS S M ET AL: "In vitro targeting of acoustically reflective immunoliposomes to fibrin under various flow conditions", JOURNAL OF DRUG TARGETING, vol. 5, no. 6, 1998, pages 507 - 518, XP008074992, ISSN: 1061-186X *
DENEFLE P P ET AL: "TOWARDS GENE THERAPY TARGETING HDL", INTERNATIONAL CONGRESS SERIES, EXCERPTA MEDICA, AMSTERDAM, NL, October 1994 (1994-10-01), pages 501 - 505, XP000572778, ISSN: 0531-5131 *
LUTTERS B C H ET AL: "Blocking endothelial adhesion molecules: A potential therapeutic strategy to combat atherogenesis", CURRENT OPINION IN LIPIDOLOGY, vol. 15, no. 5, 2004, pages 545 - 552, XP008074993, ISSN: 0957-9672 *
VILLANUEVA ET AL: "Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells", CIRCULATION, vol. 98, no. 1, 7 July 1998 (1998-07-07), pages 1 - 5, XP002092048, ISSN: 0009-7322 *
WELLER GREGORY E R ET AL: "Modulating targeted adhesion of an ultrasound contrast agent to dysfunctional endothelium.", ANNALS OF BIOMEDICAL ENGINEERING, vol. 30, no. 8, September 2002 (2002-09-01), pages 1012 - 1019, XP007901749, ISSN: 0090-6964 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066978B2 (en) 2010-05-26 2015-06-30 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers

Also Published As

Publication number Publication date
CN101189339A (zh) 2008-05-28
CA2602946A1 (fr) 2006-09-28
JP2008534508A (ja) 2008-08-28
AU2006227133A1 (en) 2006-09-28
WO2006102395A2 (fr) 2006-09-28
EP1866416A2 (fr) 2007-12-19

Similar Documents

Publication Publication Date Title
WO2006102395A3 (fr) Systemes et methodes d'administration pour le diagnostic et le traitement de maladies cardio-vasculaires
WO2007033230A3 (fr) Formulations d'anticorps anti-cd3
WO2005103081A3 (fr) Anticorps monoclonaux humains diriges contre cd20
LUC00053I9 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
WO2008070344A3 (fr) Compositions et procédés permettant une liaison sphingosine-1-phosphate
WO2007115049A3 (fr) Anticorps monoclonaux humanisés contre le facteur de croissance des hépatocytes
UA102667C2 (uk) Людське нейтралізуюче антитіло проти в7rp1
WO2008116219A3 (fr) Utilisations de l'anticorps monoclonal 8h9
WO2007059203A3 (fr) Traitement de troubles inflammatoires par des anticorps anti-récepteurs nicotiniques alpha 7
WO2007022520A3 (fr) Renfort induit par anticorps de reponse immune
WO2009112245A9 (fr) Anticorps contre le csf-1r
BRPI0611414B8 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao tweak humano, composição farmacêutica e seus usos
WO2006044643A3 (fr) Anticorps anti-cd70 et son utilisation pour le traitement et la prevention du cancer et des troubles immunitaires
WO2006099698A3 (fr) Nouvel anticorps anti-plgf
NZ595235A (en) Compositions and methods for increasing muscle growth
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
WO2006113909A3 (fr) Agents de liaison anti-cd70 humanises et utilisations
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
TW200642694A (en) Anti-M-CSF antibody compositions
WO2006122257A3 (fr) Nebulisation d'anticorps monoclonaux pour le traitement de maladies pulmonaires
EP2684889A3 (fr) Antigènes multivariables complexés avec un anticorps monoclonal humanisé cible
WO2010066803A3 (fr) Anticorps humains du facteur tissulaire
WO2019215510A8 (fr) Compositions et méthodes associées à des conjugués anticorps-médicaments anti-cd19
WO2005100405A3 (fr) Nouvelle composition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680013593.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2602946

Country of ref document: CA

Ref document number: 2008503125

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006227133

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006739249

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 4051/KOLNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006227133

Country of ref document: AU

Date of ref document: 20060322

Kind code of ref document: A